Abstract
This case series demonstrates that secukinumab therapy for paediatric patients with congenital ichthyosis is safe and has variable efficacy, similar to results from clinical trials in adults. A good response is seen in patients with the erythrodermic phenotypes, namely congenital ichthyosiform erythroderma and Netherton syndrome, with a minor response seen in lamellar ichthyosis phenotypes. Clinical data are overall lacking for the paediatric population, and this study adds some insights to the existing research.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
